MedTrace Logo

Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer

NCT05712889 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2024-11-15

No results posted yet for this study

Summary

Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer

Conditions

  • Neoplasms

Interventions

DRUG

VIP236 (Q3W)

VIP236 will be administered by IV infusion once every 3 weeks, for a 21-day cycle.

DRUG

VIP236 (Q2W)

VIP236 will be administered by IV infusion once every 2 weeks, for a 28-day cycle.

Sponsors & Collaborators

  • Vincerx Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Vincerx Study Director · Vincerx Pharma, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-24
Primary Completion
2024-10-10
Completion
2024-10-10
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05712889 on ClinicalTrials.gov